These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10770790)

  • 21. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
    el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
    J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA.
    Cen S; Huang Y; Khorchid A; Darlix JL; Wainberg MA; Kleiman L
    J Virol; 1999 May; 73(5):4485-8. PubMed ID: 10196352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.
    Schubert U; Ott DE; Chertova EN; Welker R; Tessmer U; Princiotta MF; Bennink JR; Krausslich HG; Yewdell JW
    Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13057-62. PubMed ID: 11087859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein.
    Huang M; Martin MA
    J Virol; 1997 Jun; 71(6):4472-8. PubMed ID: 9151838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.
    Ross EK; Fuerst TR; Orenstein JM; O'Neill T; Martin MA; Venkatesan S
    AIDS Res Hum Retroviruses; 1991 May; 7(5):475-83. PubMed ID: 1873082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.
    Rayner MM; Cordova BC; Meade RP; Aldrich PE; Jadhav PK; Ru Y; Lam PY
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1635-40. PubMed ID: 7979297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
    Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
    J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.
    Yu XF; Dawson L; Tian CJ; Flexner C; Dettenhofer M
    J Virol; 1998 Apr; 72(4):3412-7. PubMed ID: 9525672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.
    Erickson-Viitanen S; Manfredi J; Viitanen P; Tribe DE; Tritch R; Hutchison CA; Loeb DD; Swanstrom R
    AIDS Res Hum Retroviruses; 1989 Dec; 5(6):577-91. PubMed ID: 2692658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing.
    Bardy M; Gay B; Pébernard S; Chazal N; Courcoul M; Vigne R; Decroly E; Boulanger P
    J Gen Virol; 2001 Nov; 82(Pt 11):2719-2733. PubMed ID: 11602784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
    Jochmans D; Anders M; Keuleers I; Smeulders L; Kräusslich HG; Kraus G; Müller B
    Retrovirology; 2010 Oct; 7():89. PubMed ID: 20950436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.
    Kaplan AH; Swanstrom R
    Proc Natl Acad Sci U S A; 1991 May; 88(10):4528-32. PubMed ID: 2034693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.
    Kaplan AH; Krogstad P; Kempf DJ; Norbeck DW; Swanstrom R
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2929-33. PubMed ID: 7695287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.
    Davis DA; Yusa K; Gillim LA; Newcomb FM; Mitsuya H; Yarchoan R
    J Virol; 1999 Feb; 73(2):1156-64. PubMed ID: 9882317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Immunodeficiency Virus Gag and protease: partners in resistance.
    Fun A; Wensing AM; Verheyen J; Nijhuis M
    Retrovirology; 2012 Aug; 9():63. PubMed ID: 22867298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation.
    Moore MD; Fu W; Soheilian F; Nagashima K; Ptak RG; Pathak VK; Hu WS
    Virology; 2008 Sep; 379(1):152-60. PubMed ID: 18657842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins.
    Overton HA; McMillan DJ; Gridley SJ; Brenner J; Redshaw S; Mills JS
    Virology; 1990 Nov; 179(1):508-11. PubMed ID: 2219737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease.
    Lee SK; Potempa M; Kolli M; Özen A; Schiffer CA; Swanstrom R
    J Biol Chem; 2012 Apr; 287(16):13279-90. PubMed ID: 22334652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
    Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.